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Abstract 
Background: Klotho and FGF23 are key regulators of mineral metabolism in renal 
insufficiency. Fibroblast growth factor 23 (FGF23) levels have been shown to increase early 
in chronic kidney disease (CKD); however, the corresponding soluble Klotho levels at the 
different CKD stages are not known.  
Methods: Soluble Klotho, FGF23, parathyroid hormone (PTH), 1,25-dihydroxy vitamin D3 
(1,25D), and other parameters of mineral metabolism were measured in an observational 
cross-sectional study in 87 patients. Locally weighted scatter plot smoothing function of these 
parameters were plotted vs. estimated glomerular filtration rate (eGFR) to illustrate the 
pattern of the relationship. Linear and nonlinear regression analyses were performed to 
estimate changes of mineral metabolism parameters per one ml/min/1.73m2 decline. 
Results: From CKD 1-5, Klotho and 1,25D linearly decreased whereas both FGF23 and PTH 
showed a baseline at early CKD stages and then a curvilinear increase.Crude mean Klotho 
level declined by 4.8 pg/ml (95CI 3.5 to 6.2 pg/ml, P<0.0001) and 1,25D levels by 0.30 ng/l 
(95%CI 0.18 to 0.41 ng/l, P<0.0001) as GFR declined by 1 ml/min/1.73m2. After adjustment 
for age, gender, serum 25D levels, and concomitant medications (calcium, supplemental 
vitamin D and calcitriol), we estimated that the mean Klotho change was 3.2 pg/ml (95%CI 
1.2 to 5.2 pg/ml, P=0.0019) for each 1 ml/min/1.73m2 GFR change. FGF23 departed from the 
baseline at an eGFR of 47 ml/min/1.73m2 (95%CI 39 to 56. ml/min/1.73m2) whereas PTH 
departed at an eGFR of 34 ml/min/1.73m2 (95%CI 19 to 50 ml/min/1.73m2).  
Conclusion: Soluble Klotho and 1,25D levels decrease and FGF23 levels increase at early 
CKD stages, whereas PTH levels increase at more advanced CKD stages. 
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Introduction 
Klotho, expressed in the kidney[1, 2], parathyroid glands[3, 4], and the choroid 
plexus[5] is a single transmembrane protein whose extracellular domain is cleaved by the α-
secretases ADAM 10 and 17[6] to generate large amounts of soluble Klotho into blood, urine, 
and cerebrospinal fluid[7, 8]. Soluble Klotho activates ion channels TRPV5 and 6 in the 
nephron and the intestine[9, 10] and regulates the sodium-phosphate co-transporter type-2a 
(NaPiIIa) independently of fibroblast growth factor 23 (FGF23)[8]. 
Transmembrane Klotho acts as an important co-factor for fibroblast growth factor 23 
(FGF23). FGF23, a phosphaturic hormone produced by osteocytes, binds with only modest 
affinity to the family of FGF receptors (mainly type 1,3, and 4) whereas in vivo Klotho is 
required for FGF23 mediated receptor activation (mainly FGFR1c): it forms a complex with 
the fibroblast growth factor receptor (FGFR), thereby increasing its affinity for FGF23[11, 
12]. Thus, FGF23 and Klotho synergize to regulate phosphate homeostasis[13] by promoting 
renal phosphate excretion: they do so via reduction of the number of NaPiIIa and NaPiIIc 
phosphate co-transporters in the proximal tubule and reduction of intestinal phosphate 
absorption, the latter following a decreased renal synthesis of 1,25-dihydroxy vitamin D3 
(1,25D)[14]. 
Rodent studies indicate that soluble Klotho levels in urine and blood are highly 
correlated with renal Klotho expression[15]. Studies in patients with chronic kidney disease 
(CKD) or acute kidney injury indicate a decrease of Klotho expression with decreasing 
GFR;[16] however, these studies encompass a very limited number of patients and Klotho 
levels were only measured semi-quantitatively by western blots performed in concentrated 
urine samples. 
Cross-sectional studies have shown that the curvilinear slope of FGF23 versus estimated 
glomerular filtration rate (eGFR) ascends at CKD stage 2 to 3, whereas that of parathyroid 
hormone (PTH) versus estimated glomerular filtration rate (eGFR) ascends at CKD stage 
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3[17, 18]. However, at which CKD stage the fall of serum Klotho occurs in patients with 
CKD remains a matter of debate because a reliable assay for soluble Klotho has not been 
available until recently[19, 20], and data on the expression, function, and regulatory 
mechanisms of soluble Klotho are scarce. 
Our cross-sectional study is the first systematic determination of serum levels of Klotho, 
FGF23, PTH, 1,25D and other parameters of mineral metabolism performed in a cohort of 
patients with chronic renal insufficiency at CKD stages 1 to 5. We were examining the pattern 
of the respective changes in the mentioned parameters over the entire range of CKD stages; 
the question is relevant as Klotho or FGF23 may turn out to be important markers of early 
kidney disease, of its progression as well as of its prognosis, besides the fact that both might 
become future therapeutic targets[21]. 
Methods 
Study participants and procedures 
Eighty-seven patients at different stages of chronic kidney disease not affected by 
polycystic kidney disease or having undergone previous kidney transplantation, aged 18-84 
years were enrolled in the study. CKD patients were classified according to estimated GFR; 
CKD stage 1 (equal to or greater than 90 ml/min/1.73m2), CKD stage 2 (60 to 89 
ml/min/1.73m2), CKD stage 3 (30 to 59 ml/min/1.73m2), CKD stage 4 (15 to 29 
ml/min/1.73m2) and CKD stage 5 (lower than 15 ml/min/1.73m2 or dialysis [5D]).Twenty one 
healthy volunteers, aged 37 to 62 years, without a medical history of renal disease, and 
screened negatively for microhematuria or microalbuminuriaserved as control group. 
Sitting blood pressure was measured by a nurse, a blood sample was drawn and a spot urine 
sample (2nd fasting morning urine, after voiding the 1st urine of the day prior to the visit to the 
clinics) was collected between 8 a.m. and 10 a.m. Hemodialysis patients were analyzed at 
their steady state condition: after the long interval, blood was taking immediately after placing 
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the dialysis needle and thus before start of dialysis treatment. Residual renal function in 
CKD5D patients was calculated according to guidelines for the measurement of renal function 
[22] applying the formula of Daugirdas[23]. Briefly, the mean of urea and creatinine 
clearance, determined from 48-h urine collections and normalized to 1.73 m2 were calculated. 
In anuric patients the value was set to zero. 
The serum and urine aliquots were stored at -80°C. Blood was analyzed for Klotho, 
FGF23, PTH, phosphate, ionized calcium, creatinine, 25-hydroxyvitamin D (25D) and 1,25D. 
Spot urine was analyzed for phosphate and creatinine.  
The study was conducted according to the Declaration of Helsinki and the guidelines of 
Good Clinical Practice (GCP) and was approved by the local Ethics Committee. All patients 
gave written, informed consent. 
 
Analytical methods 
A novel ELISA method detecting human soluble Klotho has been developed first by 
establishing a monoclonal antibody with strong affinity for human Klotho protein, 
recognizing with high selectivity the tertiary protein structure of its extracellular domain 
(Immuno-Biological Laboratories Co., Ltd. Japan). The established protein detection method 
has been subsequently tested comparing the serum Klotho levels of human healthy volunteers 
with a human case where the Klotho gene carries a mutation that hinders the expression of 
Klotho in the test subject. The results of the analysis indicated that the ELISA system can 
specifically detect and measure the circulating serum Klotho levels in humans.[24] We further 
validated the assay in patients affected by autosomal dominant polycystic kidney disease: 
Low serum Klotho levels were found to constrain the phosphaturic effect of FGF23 and to 
correlate inversely with cyst growth and kidney volume[19].The respective intra-assay and 
intra-subject coefficient of variations of Klotho were 2.6±1.1% and 5.6±2.1% in the present 
study. 
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The levels of carboxy-terminal FGF23 (2nd generation, Immutopics Inc., San Clemente 
CA, USA) and intact PTH (2nd generation, Biomerica Inc., Newport Beach CA, USA) were 
measured in serum by enzyme-linked immunosorbent assay (ELISA) according to the 
manufacturer’s protocol. As previously published, we and others have shown that intact 
FGF23 and c-term FGF23 levels closely correlate in early and late CKD stages.[18, 25-27] 
Serum 25D and 1,25D have been determined using the radioimmunoassay-kits from 
Diasorin (Stillwater, MN, USA) and Immunodiagnostic Systems (Fountain Hills, AZ, USA), 
respectively. Phosphate concentrations were measured in serum and urine using standard 
methods. Creatinine in serum and urine was assayed by the IDMS traceable modified Jaffé 
method. The glomerular filtration rate was estimated by using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation.[28]Phosphate and creatinine (IDMS-
traceable modified Jaffé method) concentrations were measured in serum and urine. The ratio 
of the maximum rate of tubular phosphate reabsorption to the glomerular filtration rate 
(TmP/GFR) was calculated as follow: TmP/GFR in mmol/l = PP-[UP x PCrea/UCrea] where PP, 
UP, PCrea, and UCrea refer to the plasma and urinary concentration of phosphate and creatinine, 
respectively.[29] TmP/GFR allows to estimate net renal phosphate transport and is referred to 
as the theoretical renal phosphate threshold.[30] This corresponds to the theoretical lower 
limit of plasma phosphate below which all filtered phosphate would be absorbed (normal 
range 0.80-1.35 mmol/l). 
 
Statistical Analysis 
LOWESS (locally weighted scatter plot smoothing) function of Klotho, FGF23, PTH, 1,25D, 
and serum phosphate versus eGFR were fitted by the default function of the STATA version 
11.2 software (STAT Corp., College Station, TX) with a bandwidth of 0.8. LOWESS is 
a modeling methods designed to address situations in which the classical linear regression 
procedures do not perform well[31]. At each point in the data set a low-degree polynomial is 
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fitted to a subset of the data, with explanatory variable values near the point whose response 
is being estimated. LOWESS combines linear least squares regression with the flexibility 
of nonlinear regression and does not require to specify a global function of any form to fit a 
model. LOWESS allows determining the relationship without having specified a global 
function of any form to fit a model, whereas linear models “force” the line to fit the a priori 
model, e.g. quadratic function.  
Based on the LOWESS shape, a linear model was fitted for Klotho and 1,25D and the 
crude mean change for each 1 ml/min/1.73 m2 eGFR was estimated. Vitamin D increases 
Klotho expression in vivo in mice[32] and in vitro in a variety of cell lines[33]. Therefore, 
Klotho related data were adjusted by fitting an a priori model containing the following 
variables: vitamin D supplementation, 1,25D treatment, calcium administration (calcium 
acetate, calcium supplement), calcium-free phosphate binder (sevelamer, lanthanum), and 
serum 25D levels. Thus, the estimated mean changes of Klotho and 1,25D were adjusted for 
treatment with vitamin D compounds and 25D levels, covariates that potentially influence 
these profiles over eGFR. The association between FGF23 and PTH with eGFR was not linear 
and thus we fitted a segmented model consisting of smoothly fitted baseline and quadratic 
function to estimate the departure point of the curve from the baseline.  
In anadditional analysis, differences among the CKD stages and healthy volunteers were 
comparedby one-way analyses of variance. When the difference was significant, 
statisticalcomparisons were performed by using Dunnett’s post hoc test with the healthy 
volunteers as a reference group. Spearman's rank correlation coefficient was calculated to 
measure statistical dependence between two variables. 
All P values were two-sided for the comparison between the groups and values below 
0.05 were considered as statistically significant. Statistical analyses were performed using 
SAS statistical software version 9.2. (SAS Institute Inc., Cary, NC). 
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Results 
Patients were studied at the outpatient clinic of the Division of Nephrology at the 
University Hospital of Zurich, Switzerland from March 2010 to May 2011. Table 1 shows the 
characteristics of 87 CKD patients and 21 healthy volunteers. The patients were classified into 
CKD stages according to the CKD EPI equation: 19% of the participants belonged to CKD 
stage 1, 22% to stage 2, 13% to stage 3, 23% to stage 4 and 23% to stage 5 (18 of 20 patients 
on chronic hemodialysis treatment, median dialysis vintage 1.4 years). Causes of 
nephropathies in CKD patients were: hypertensive nephropathy (n=20, 10% biopsy 
confirmed), IgA-nephropathy (n=12, 83% biopsy confirmed), diabetic nephropathy (n=6, 
33% biopsy confirmed), focal segmental glomerulosclerosis (n=10, 100% biopsy confirmed), 
lupus nephritis (n=5, 80% biopsy confirmed), other glomerulonephritides (n=13, 46% biopsy 
confirmed), other kidney diseases (n=16, 81% biopsy-proven), and CKD of unknown etiology 
(n=5). Supplemental Table 1 displays disease classifications according to the CKD stages. In 
the CKD 4 and 5 strata, diabetic and hypertensive patients were enriched. The frequency of 
1,25D and phosphate binder treatment increased with advancing CKD stages. At any CKD 
stage, at least 40% of the patients were supplemented with nutritional vitamin D (Table 1). 
None of the patients were currently or had been treated in the past with bisphosphonates.  
 
Relationship between Klotho, GFR and parameters of mineral metabolism 
Klotho, 1,25D, FGF23 and PTH levels were plotted versus eGFR and the respective 
relationships analyzed by the LOWESS function, a statistical technique without assumption 
on the shape of the relationship.  
Figure 1a reveals that serum Klotho and eGFR were associated linearly. Klotho levels 
continuously declined with progressive degree of severity of renal insufficiency; this fitted a 
linear model (r2=0.41, P<0.0001) and it was estimated that the crude mean Klotho level 
declined by 4.8 pg/ml (95CI 3.5 to 6.2 pg/ml, P<0.0001) as GFR declined by 1 ml/min. After 
9of 23 
adjustment for age, gender, serum 25D levels, and concomitant medications (calcium, 
supplemental vitamin D and calcitriol), we estimated that the mean Klotho change was 3.2 
pg/ml (95%CI 1.2 to 5.2 pg/ml, P=0.0019) for each 1 ml/min GFR change. We noted that 
many patients had low 25D levels. To rule out for the possibility that low Klotho levels might 
just reflect vitamin D deficiency, we separately estimated Klotho changes in subjects with 
serum 25D levels of 20 μg/l and above (n=37): Crude and adjusted mean Klotho level 
declined by 4.9 pg/ml (95CI 3.0 to 6.8 pg/ml, P<0.0001) and by 3.6 pg/ml (95CI 0.4 to 6.8 
pg/ml, P=0.03), respectively as GFR declined by 1 ml/min. We obtained similar results when 
separately analyzing subjects without vitamin D supplementation (n=43): Crude and adjusted 
mean Klotho level declined by 4.7 pg/ml (95CI 2.8 to 6.5 pg/ml, P<0.0001) and by 3.7 pg/ml 
(95CI 0.9 to 6.5 pg/ml, P=0.01), respectively as GFR declined by 1 ml/min. 
We assessed the association of Klotho with other parameters of mineral metabolism 
(Table 2). In the univariate analysis Klotho was associated with serum calcium, phosphate, 
1,25D, FGF23 and PTH. However these associations were attenuated after adjusting for age, 
gender and estimated GFR. Age and eGFR remained independently associated with Klotho, 
underlining the importance of both factors when interpreting serum Klotho levels. 
The serum Klotho levels among 17 hemodialysis patients meeting the criteria for 
secondary hyperparathyroidism (PTH >65 ng/ml, serum phosphate >1.1 mmol/l, serum 
calcium <2.6 mmol/l and calcitriol treatment <1 µg/week[34, 35]) were 463.4 ± 237.0 pg/ml 
(median 375.0 pg/ml, IQR 273.7 to 618.9 pg/ml). 
 
Relationship between serum levels of 1,25D, FGF23 and PTH with eGFR.  
Figure 1b confirms that 1,25D and eGFR are linearly associated and 1,25Dlevels 
decline with progressive GFR loss justifying the fitting of a linear model. We estimated that 
the crude mean 1,25D levels decrease by 0.30 ng/l (95%CI 0.18 to 0.41 ng/l, P<0.0001) as 
eGFR declines by 1 ml/min. The adjustment for age, gender, serum 25D levels, and the 
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concomitant medications did only marginally change the estimated 1,25D slope: 0.30 ng/l per 
1 ml eGFR (0.10 to 0.49 ng/l per 1 ml eGFR; P=0.0036).  
Based on the visual inspection of the LOWESS plots, FGF23 and PTH were not linearly 
associated with eGFR. Thus, we fitted a segmented, nonlinear model that consists of two 
segments connected in a smooth fashion, and we estimated the departure point of the curve 
from the baseline. The iterative optimization converges after 6(FGF23 vs. eGFR) and 7 (PTH 
vs. eGFR) iterations, respectively. We estimated that the FGF23 curve departs from the 
baseline (81 RU/ml) at a GFR of 47 ml/min (95%CI 39 to 56 ml/min) whereas the PTH curve 
departs from the baseline (58 ng/ml), at a eGFR of 34 ml/min (95%CI 19 to 50 ml/min). 
However, it is noteworthy that, in their respective relationship to eGFR, FGF23 and PTH both 
showed a baseline at approximately CKD stages 1 to 3 for PTH and 1 to 2 for FGF23 and an 
exponential increase at higher respective CKD stages in the LOWESS plots (Figures 1c and 
1d), whereas the segmented model estimated a later departure from the baseline indicating a 
Type 2 error pointing to the fact that the study is underpowered for this specific type of 
analysis (which was not the primary focus of the analysis).  
 
Phosphate, calcium and 25-hydroxy vitamin D 
Mean serum phosphate levels increased only modestly in patients at higher CKD stages: 
0.96 mmol/l ± 0.17 mmol/l in CKD 1 to 1.69 mmol/l ± 0.48 mmol/l in CKD5 (Table 3). 
Hyperphosphatemia (> 1.1 mmol/l) was present in 46% of the participating subjects, mostly 
in patients with CKD stages 4 and 5, as expected. The LOWESS function of serum phosphate 
versus eGFR indicated a baseline at early CKD stages and an exponential increase at 
advanced CKD stages (Figure 2a). The departure point of the curve from the baseline was at 
an eGFR of 35 ml/min (95%CI 22 to 49 ml/min) estimated by fitting a segmented nonlinear 
regression model. TmP/GFR remained normal and unchanged for patients at CKD stage 1 to 3 
and then declined at stage 4. 
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The ionized calcium levels remained unchanged across CKD stages 1 to 5 and the 
LOWESS function remained within the normal range (1.10 mmol/l - 1.30 mmol/l) (Figure 
2b). The serum levels of 25-hydroxy vitamin D (25D) also remained unchanged across CKD 
stages 1 – 5 (Figure 2C). 
 
Differences among the CKD stages and healthy volunteers 
Klotho levels were lower among CKD stage 5 patients compared to age-matched 
healthy volunteers when applying apost hoctest adjusted for multiple testing and using 
volunteers as a reference group. The Klotho levels decreased approximately by half from 
CKD 1 to CKD 5 (mean difference -504.1 pg/ml (95%CI -747.4 to -260.8; P<0.05). Serum 
levels of FGF23 in patients at CKD stages 4 and 5 were different from those obtained in 
healthy volunteers (p<0.05), whereas for PTH the serum levels were only different from 
healthy volunteers at CKD stage 5 (p<0.05). Only patients at CKD stage 5 had serum 
phosphate levels different from those observed in healthy volunteers, similar to what was seen 
for PTH. TmP/GFR values were similar among CKD patients and volunteers (Table 3). 
 
Discussion 
In our present study, we illustrate the concurrent respective patterns of the serum levels of the 
6 key actors which govern mineral metabolism in renal insufficiency, i.e. Klotho, 1,25D, 
FGF23, PTH, phosphate and calcium: serum levels of soluble alpha-Klotho and 1,25D 
decrease in parallel with the progressive decline in glomerular filtration rate,whereas serum 
levels of FGF23 rise (Figure 3). All do so before a rise in serum levels of PTH occurs. 
Ultimately, i.e. at CKD stage 4 and onwards, serum levels of phosphate start rising, whereas 
serum levels of ionized calciumremain unchanged across all CKD stages included in this 
cross-sectional study. The study also confirms the low levels of serum Klotho in hemodialysis 
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patients with secondary hyperparathyroidism [36]. 
It is of importance to mention that the cross-sectional study design precludes definitive 
conclusions on the temporal sequence. Furthermore, the relatively low number of study 
subjects and the substantial variation of PTH and FGF23 levels preclude a precise estimation 
of the departure from the baseline. However, it is noteworthy that the sequence suggested by 
the present study on 87 patients confirms that recently published on 3879 patients by Isakova 
et al.[18]who pointed to the fact that the rise in serum FGF23 might precede the rise in serum 
PTH in the course of development of renal insufficiency. As to the rise in FGF23 itself in a 
state of Klotho deficiency, it has been envisioned as the consequence of phosphorous 
accumulation as recently demonstrated by preclinical studies which showed absence of said 
rise in klotho-/- mice fed a low phosphate diet[21]. However, several investigators have 
observed a modest reduction in serum phosphate during early CKD [36, 37] and our own data 
also point in this direction.  
The present study illustrates the fact that serum levels of both 1,25D and Klotho decline 
“hand in hand” with progression of renal insufficiency. Given the current limitations of the 
respective techniques, it remains speculative to declare which of both levels declines first, i.e. 
what is the cause and what is the consequence: on the one hand, Tsujikama et al suggested 
that Klotho might have an enzymatic ability to modify a receptor or ligand autonomously 
influencing the activity of 1-alpha hydroxylase; on the other hand, the same authors 
demonstrated that 1,25D itself modulates the expression of Klotho[37]. 
Earlier studies reported Klotho levels in CKD patients and volunteers: On one hand, Sugiura 
and colleagues reported serum Klotho levels of 1413 pg/ml among 30 elderly CKD patients 
(serum creatinine values of 1.63 ± 1.35 mg/dl) and 404 pg/ml among 10 healthy adults, aged 
20 to 44 years, suggesting an elevation of Klotho in CKD patients [38]. The Klotho levels of 
these healthy volunteers are substantially lower than values previously reported in the 
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literature and thus may indicate selection bias or technical errors. Although the CKD stages of 
the patients were not reported, the negative lower boundary of the 95% confidence interval of 
the serum creatinine values suggests that the CKD stages were not evenly distributed and thus 
the rather high mean Klotho level in CKD is possibly due to an enrichment of patients at early 
CKD stages. The fact that FGF23 levels were similar in healthy volunteers and CKD patients 
further supports the hypothesis that patients at CKD stages 1 and 2 were selected 
preferentially in that study. On the other hand, Akimoto and colleagues reported that the 
amount of urinary Klotho levels correlated positively with residual glomerular function in 36 
peritoneal dialysis patients whereas an association between serum Klotho levels and residual 
function was not found [39]. Similarly, we did not find an association between residual 
function and serum Klotho levels among 13 non-anuric hemodialysis patients (Spearman 
r=0.2, p-value 0.4); however this is a subgroup analysis that is most likely underpowered. 
It has been postulated by some that an initial renal tubular damage leads to down-regulation 
of the expression of both Klotho and 1-alpha-hydroxylase, and that the ensuing cascade 
comprising the rise in FGF23 and in PTH is the consequence: Indeed, insufficient production 
of Klotho known to occur at the level of both the parathyroid gland and the nephron in 
condition of renal insufficiency[40, 41] leads to peripheral resistance to FGF23 at both 
anatomical sites, and FGF23 thus can no longer suppress PTH secretion nor maintain 
phosphate homeostasis, as already suggested by Kuro-o[17].  
Alternatively, it has been suggested[18] that the initial increase in early CKD actually causes 
the down regulation of Klotho via reduced 1,25D. Therefore further studies, in particular 
prospective longitudinal studies remain to be carried out to clarify this point and to determine 
the temporal sequence of the observed hormonal changes inasmuch as the vitamin D 
administration itself might play a role. 
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In conclusion, our data elevate the newly assayable serum level of soluble alpha-Klotho to the 
rank of potentially important markers for early detection of kidney damage and it triggers new 
hopes for effective monitoring and future therapeutic interventions. 
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Figures Legends 
Figure 1 Scatter plot graphs of with locally weighted scatter plot smoothing (LOWESS) lines 
of A) Klotho, B) 1,25-dihydroxy-vitamin D3 (1,25D), C) carboxy-terminal fibroblast growth 
factor 23 (FGF23) and D) intact parathyroid hormone (PTH) versus estimated glomerular 
filtration rate (eGFR) in chronic kidney disease patients Each symbol represents one patient.  
 
Figure 2 Scatter plot graphs with locally weighted scatter plot smoothing (LOWESS) linesof 
A) serum phosphate, B) ionized calcium and C) 25-hydroxy-vitamin D (25D), versus 
estimated glomerular filtration rate (eGFR) in chronic kidney disease patients. Each symbol 
represents one patient.  
 
Figure 3 Overlaid locally weighted scatter plot smoothing (LOWESS) lines for Klotho 
(pg/ml), 1,25-dihydroxy-vitamin D3 (1,25D, ng/l x 10-3), carboxy-terminal fibroblast growth 
factor 23 (FGF23, RU/ml), intact parathyroid hormone (PTH, ng/ml) and serum phosphate 
(mol/l x 10-3) versus estimated glomerular filtration rate (eGFR, ml/min/1.73m2) in chronic 
kidney disease patients. 
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Tables 
Table 1.Characteristics of patients with chronic kidney disease (CKD) and healthy volunteers (HV). 
 CKD 1 
N=17 
CKD 2 
N=19 
CKD 3 
N =11 
CKD 4 
N=20 
CKD 5 
N=20 
HV 
N=21 
Age– years 41 ± 14 40 ± 12 57 ± 15 64 ± 12 61 ± 17 48± 8 
Sex– no. (%)       
     Female 7 (41) 12 (63) 6 (55) 9 (45) 8 (40) 9 (43) 
     Male 10 (59) 7 (37) 5 (45) 11 (55) 12 (60) 12 (57) 
Body mass index - kg per m2 28 ± 6 23 ± 5 28 ± 4 28 ± 6 24 ± 6 24 ± 2 
Creatinine – mg/dl 0.8 ± 0.2 1.0 ± 0.2 1.5 ± 0.3 2.5 ± 0.7 6.6 ± 2.8 0.9 ± 0.1 
eGFR- ml/min per 1.73m2 104.1 ± 11.3 81.1 ± 16.5 42.6 ± 6.0 25.3 ± 5.8 5.7 ± 4.9 91.2 ± 14.1 
Blood pressure– mmHg       
     Systolic 139 ± 13 130 ± 13 144 ± 21 145 ± 19 138 ± 26 129± 15 
     Diastolic 83 ± 10 84 ± 8 78 ± 14 79 ± 12 69 ± 21 80 ± 13 
Urinary protein excretion       
     Protein-to-creatinine ratio – g/mmol 0.04 (0.01, 0.06) 0.01 (0.01, 0.04) 0.03 (0.01, 0.06) 0.02 (0.01, 0.07) NA 0.02 (0.01, 0.02) 
Medication- no. (%)       
 25-hydroxy-vitaminsupplement 7 (41) 7 (37) 9 (82) 13 (65) 8 (40) 0 
1,25-dihydroxy vitamin D3treatment 0 (0) 1 (5) 1 (9) 5 (25) 4 (20) 0 
     Calcium-free phosphate binder 0 (0) 0 (0) 0 (0) 2 (10) 9 (45) 0 
     Calcium administration 4 (24) 5 (26) 1 (9) 5 (25) 10 (50) 0 
     Bicarbonate supplement 0 (0 0 (0) 0 (0) 4 (20) 1 (5) 0 
     Diuretics 1 (6) 2 (11) 4 (36) 14 (70) 6 (30) 0 
     Prednisone 3 (18) 6 (32) 4 (36) 2 (10) 3 (15) 0 
Abbreviations: eGFR – estimated glomerular filtration rate. Values are means ± standard deviation and numbers (percentage) 
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Table 2.Association of Klotho levels with other serum parameters of mineral metabolism in CKD patients: β estimates and (p-values) of the 
univariate and multivariate regression analysis. 
 
Regression models Calcium Phosphate 1,25 dihydroxy-
vitamin D3 
FGF23* PTH* 
Univariate      
   Klotho* -0.3 (<0.0001) -0.2 (0.01) 0.003 (<0.001) -0.2 (<0.001) -0.2 (<0.001) 
Multivariate 
   Klotho* 
   Age (years) 
Gender (male=1) 
   eGFR† 
 
-0.02 (0.9) 
-0.004 (0.01) 
0.01 (0.03) 
0.001 (0.02) 
 
-0.01 (0.2) 
-0.004 (0.01) 
0.03 (0.04) 
0.001 (0.03) 
 
0.001 (0.5) 
0.001 (0.01) 
0.01 (0.7) 
0.001 (0.03) 
 
-0.002 (1.0) 
-0.003 (0.01) 
0.01 (0.7) 
0.002 (0.06) 
 
0.03 (0.7) 
-0.004 (0.01) 
0.009 (0.8) 
0.002 (0.03) 
* log transformed, † estimated GFR according to the CKD-EPI formula. 
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Table 3.Parameters of phosphate metabolism in patients with chronic kidney disease (CKD) and healthy volunteers (HV). 
 
Parameter CKD 1 
N=17 
CKD 2 
N=19 
CKD 3 
N =11 
CKD 4 
N=20 
CKD 5 
N=20 
HV 
N=21 
Serum       
Klotho - pg/ml 
 Q1/Median/Q3 
964.3 ± 398.8 
703.2/880.1/1159.8 
820.2 ± 283.4 
616.2/749.3/999.1 
638.1 ± 128.7 
423.9/622.6/684.9 
539.7 ± 165.1 
415.1/490.2/640.8 
460.2 ± 222.8 
282.2/368.3/612.9 
1078.6 ± 1810.2 
428.7/600.3/861.5 
FGF23 - RU/ml 
 Q1/Median/Q3 
89.9 ± 54.3 
51.1/95.5/101.4 
65.1 ± 41.7 
38.2/50.8/82.9 
137.7 ± 45.9 
50.8/140.1/161.3 
377.2 ± 370.3 
141.6/307.0/434.0 
1200.6 ± 416.4 
910.0/1356.7/1586.4 
24.8 ± 13.7 
18.3/24.2/32.4 
PTH - ng/ml 
 Q1/Median/Q3 
43.0 ± 17.0 
32.7/42.3/52.8 
40.4 ± 16.6 
31.2/39.6/45.9 
87.4 ± 63.8 
25.9/76.6/88.1 
129.1 ± 71.2 
87.2/119.4/156.7 
422.8 ± 392.7 
196.9/314.2/492.4 
55.6 ± 25.4 
36.4/46.2/67.1 
25-hydroxy-vitamin D - μg/l 
 Q1/Median/Q3 
15.1 ± 8.9 
8.5/15.4/20.8 
20.4 ± 8.2 
14.7/20.9/24.0 
17.6 ± 6.0 
7.9/19.3/19.8 
21.9 ± 12.5 
12.7/18.8/27.3 
25.9 ± 12.4 
16.7/26.2/34.1 
21.6 ± 9.1 
15.7/18.5/25.6 
1,25-dihydroxy-vitamin D3- ng/l 
 Q1/Median/Q3 
48.5 ± 25.9 
34.3/41.6/55.4 
45.7 ± 19.6 
29.8/48.0/51.7 
31.7 ± 12.7 
13.0/35.4/42.3 
27.12 ± 8.7 
19.3/30.4/33.0 
21.8 ± 15.0 
13.2/13.8/26.5 
65.4 ± 24.4 
48.9/61.6/79.4 
Phosphate - mmol/l 
 Q1/Median/Q3 
0.96 ± 0.17 
0.84/0.96/1.08 
1.02 ± 0.24 
0.85/1.02/1.24 
1.01 ± 0.22 
0.62/1.03/1.11 
1.15 ± 0.21 
1.04/1.09/1.30 
1.69 ± 0.48 
1.33/1.58/1.99 
1.00 ± 0.19 
0.86/0.97/1.14 
Ionized Calcium - mmol/l 
 Q1/Median/Q3 
1.20 ± 0.05 
1.18/1.20/1.21 
1.24 ± 0.09 
1.20/1.22/1.25 
1.23 ± 0.05 
1.18/1.22/1.24 
1.22 ± 0.06 
1.17/1.21/1.25 
1.19 ± 0.08 
1.14/1.17/1.22 
NA 
Calcium - mmol/l 
 Q1/Median/Q3 
2.32 ± 0.13 
2.26/2.32/2.40 
2.32 ± 0.13 
2.22/2.33/2.41 
2.39 ± 0.16 
2.28/2.36/2.44 
2.36 ± 0.14 
2.25/2.34/2.47 
2.33 ± 0.17 
2.22/2.30/2.41 
2.22 ± 0.09 
2.18/2.24/2.28 
       
Spot Urine       
Phosphate - mmol/l 
 Q1/Median/Q3 
12.8 ± 5.8 
8.1/13.1/16.1 
16.5 ± 12.9 
4.1/15.3/21.2 
9.7 ± 4.6 
5.4/8.7/11.2 
12.5 ± 5.4 
9.4/11.3/15.9 - 
16.7 ± 12.6 
7.9/14.2/19.2 
TmP/GFR - mmol/l/GFR 
 Q1/Median/Q3 
0.85 ± 0.16 
0.74/0.81/0.97 
0.89 ± 0.23 
0.69/0.85/1.13 
0.86 ± 0.25 
0.42/0.91/1.03 
0.72 ± 0.16 
0.60/0.78/0.85 - 
0.87 ± 0.21 
0.70/0.88/1.02 
Abbreviations: Q1 - 0.25 quartile; Q3 - 0.75 quartile, 1,25-dihydroxy-vitamin D3 (1,25D), FGF23 - carboxy-terminal fibroblast growth factor 23, 
PTH - intact parathyroid hormone, TmP/GFR - Tubular maximum phosphate reabsorption per ml of glomerular filtrate. 
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Supplemental Material 
 
Supplemental Table 1: Disease classifications according to CKD stages 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: IGAN - IgA nephropathy, FSGS – focal segmental glomerulosclerosis, SLS – 
systemic lupus nephritis, GN – glomerulonephritis. 
Disease  CKD stages 
categories 1 2 3 4 5 
Hypertensive Nephropathy 0 1 4 11 4 
IGAN 5 2 2 1 2 
Diabetes mellitus 0 0 0 3 3 
FSGS 2 2 3 1 2 
SLE 1 2 0 1 1 
Other GN 5 3 1 1 3 
Other kidney disease 4 7 1 1 3 
Unknown 0 2 0 1 2 
